Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ImmunityBio, Inc. (IBRX)

4.005   0.055 (1.39%) 01-27 16:00
Open: 3.9 Pre. Close: 3.95
High: 4.089 Low: 3.9
Volume: 1,023,819 Market Cap: 1,603(M)

Technical analysis

as of: 2023-01-27 4:45:21 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6     One year: 6.95
Support: Support1: 3.82    Support2: 3.18
Resistance: Resistance1: 5.14    Resistance2: 5.95
Pivot: 4.44
Moving Average: MA(5): 4.25     MA(20): 4.52
MA(100): 5.25     MA(250): 4.9
MACD: MACD(12,26): -0.4     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 13.6     %D(3): 19.7
RSI: RSI(14): 32.5
52-week: High: 7.84  Low: 2.59
Average Vol(K): 3-Month: 1,636 (K)  10-Days: 1,547 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IBRX ] has closed above bottom band by 4.5%. Bollinger Bands are 43.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.1 - 4.13 4.13 - 4.15
Low: 3.83 - 3.87 3.87 - 3.9
Close: 3.95 - 4.01 4.01 - 4.05

Company Description

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Headline News

Thu, 26 Jan 2023
ImmunityBio Inc. (IBRX) is on the roll with an average volume of 1.63 ... - Invest Chronicle

Mon, 23 Jan 2023
ImmunityBio Inc. (NASDAQ: IBRX) Forecast To Gain 48.78% To Hit ... - Marketing Sentinel

Mon, 23 Jan 2023
Short Interest in ImmunityBio, Inc. (NASDAQ:IBRX) Declines By 5.5% - MarketBeat

Thu, 19 Jan 2023
ImmunityBio Reports Positive Data From Metastatic Pancreatic Cancer Study -

Tue, 10 Jan 2023
ImmunityBio (IBRX) Stock: Relief For Bladder Cancer Not Assured - Seeking Alpha

Fri, 06 Jan 2023
ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances ... - Seeking Alpha

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 400 (M)
% Held by Insiders 9.398e+007 (%)
% Held by Institutions 79.1 (%)
Shares Short 24,080 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.1549e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -59
Return on Assets (ttm) 625.8
Return on Equity (ttm) -73.2
Qtrly Rev. Growth 557000
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.53
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -318 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 2.5
Price to Book value 0
Price to Sales 1069.25
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 2.373e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.